354 related articles for article (PubMed ID: 8521555)
1. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
Schwartz PJ; Priori SG; Locati EH; Napolitano C; Cantù F; Towbin JA; Keating MT; Hammoude H; Brown AM; Chen LS; Colatsky TJ
Circulation; 1995 Dec; 92(12):3381-6. PubMed ID: 8521555
[TBL] [Abstract][Full Text] [Related]
2. Molecular biology of the long QT syndrome: impact on management.
Priori SG; Napolitano C; Paganini V; Cantù F; Schwartz PJ
Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 2):2052-7. PubMed ID: 9272507
[TBL] [Abstract][Full Text] [Related]
3. A molecular basis for the therapy of the long QT syndrome.
Priori SG; Napolitano C; Schwartz PJ
Arch Mal Coeur Vaiss; 1996 Sep; 89(9):1185-7. PubMed ID: 8952843
[TBL] [Abstract][Full Text] [Related]
4. The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology.
Priori SG; Cantù F; Schwartz PJ
Schweiz Med Wochenschr; 1996 Oct; 126(41):1727-31. PubMed ID: 8893413
[TBL] [Abstract][Full Text] [Related]
5. Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome.
Priori SG; Napolitano C; Cantù F; Brown AM; Schwartz PJ
Circ Res; 1996 Jun; 78(6):1009-15. PubMed ID: 8635231
[TBL] [Abstract][Full Text] [Related]
6. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
Sicouri S; Antzelevitch D; Heilmann C; Antzelevitch C
J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1280-90. PubMed ID: 9395171
[TBL] [Abstract][Full Text] [Related]
7. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome.
Shimizu W; Antzelevitch C
Circulation; 1997 Sep; 96(6):2038-47. PubMed ID: 9323097
[TBL] [Abstract][Full Text] [Related]
8. Sodium channel blockers in the management of long QT syndrome types 3 and 2: A system review and meta-analysis.
Yang Y; Lv TT; Li SY; Zhang P
J Cardiovasc Electrophysiol; 2021 Nov; 32(11):3057-3067. PubMed ID: 34427958
[TBL] [Abstract][Full Text] [Related]
9. Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome.
Bos JM; Crotti L; Rohatgi RK; Castelletti S; Dagradi F; Schwartz PJ; Ackerman MJ
Circ Arrhythm Electrophysiol; 2019 May; 12(5):e007280. PubMed ID: 31006312
[TBL] [Abstract][Full Text] [Related]
10. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
Windle JR; Geletka RC; Moss AJ; Zareba W; Atkins DL
Ann Noninvasive Electrocardiol; 2001 Apr; 6(2):153-8. PubMed ID: 11333173
[TBL] [Abstract][Full Text] [Related]
11. Genetics, molecular mechanisms and management of long QT syndrome.
Wang Q; Chen Q; Towbin JA
Ann Med; 1998 Feb; 30(1):58-65. PubMed ID: 9556090
[TBL] [Abstract][Full Text] [Related]
12. [Molecular genetics in the hereditary form of long QT syndrome].
Georgijević Milić L
Med Pregl; 2000; 53(1-2):51-4. PubMed ID: 10953551
[TBL] [Abstract][Full Text] [Related]
13. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype.
Zareba W; Moss AJ; Locati EH; Lehmann MH; Peterson DR; Hall WJ; Schwartz PJ; Vincent GM; Priori SG; Benhorin J; Towbin JA; Robinson JL; Andrews ML; Napolitano C; Timothy K; Zhang L; Medina A;
J Am Coll Cardiol; 2003 Jul; 42(1):103-9. PubMed ID: 12849668
[TBL] [Abstract][Full Text] [Related]
14. Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3.
Mazzanti A; Maragna R; Faragli A; Monteforte N; Bloise R; Memmi M; Novelli V; Baiardi P; Bagnardi V; Etheridge SP; Napolitano C; Priori SG
J Am Coll Cardiol; 2016 Mar; 67(9):1053-1058. PubMed ID: 26940925
[TBL] [Abstract][Full Text] [Related]
15. Sinus node function and ventricular repolarization during exercise stress test in long QT syndrome patients with KvLQT1 and HERG potassium channel defects.
Swan H; Viitasalo M; Piippo K; Laitinen P; Kontula K; Toivonen L
J Am Coll Cardiol; 1999 Sep; 34(3):823-9. PubMed ID: 10483966
[TBL] [Abstract][Full Text] [Related]
16. Gene-specific differences in the circadian variation of ventricular repolarization in the long QT syndrome: a key to sudden death during sleep?
Stramba-Badiale M; Priori SG; Napolitano C; Locati EH; Viñolas X; Haverkamp W; Schulze-Bahr E; Goulene K; Schwartz PJ
Ital Heart J; 2000 May; 1(5):323-8. PubMed ID: 10832806
[TBL] [Abstract][Full Text] [Related]
17. Risk stratification in the long-QT syndrome.
Priori SG; Schwartz PJ; Napolitano C; Bloise R; Ronchetti E; Grillo M; Vicentini A; Spazzolini C; Nastoli J; Bottelli G; Folli R; Cappelletti D
N Engl J Med; 2003 May; 348(19):1866-74. PubMed ID: 12736279
[TBL] [Abstract][Full Text] [Related]
18. Epinephrine bolus test in detecting long QT syndrome mutation carriers with indeterminable electrocardiographic phenotype.
Hekkala AM; Swan H; Viitasalo M; Väänänen H; Toivonen L
Ann Noninvasive Electrocardiol; 2011 Apr; 16(2):172-9. PubMed ID: 21496168
[TBL] [Abstract][Full Text] [Related]
19. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients.
Ruan Y; Liu N; Bloise R; Napolitano C; Priori SG
Circulation; 2007 Sep; 116(10):1137-44. PubMed ID: 17698727
[TBL] [Abstract][Full Text] [Related]
20. Cellular basis for long QT, transmural dispersion of repolarization, and torsade de pointes in the long QT syndrome.
Shimizu W; Antzelevitch C
J Electrocardiol; 1999; 32 Suppl():177-84. PubMed ID: 10688323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]